Your browser doesn't support javascript.
loading
Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities.
Abdel-Wahab, May; Coleman, C Norman; Eriksen, Jesper Grau; Lee, Peter; Kraus, Ryan; Harsdorf, Ekaterina; Lee, Becky; Dicker, Adam; Hahn, Ezra; Agarwal, Jai Prakash; Prasanna, Pataje G S; MacManus, Michael; Keall, Paul; Mayr, Nina A; Jereczek-Fossa, Barbara Alicja; Giammarile, Francesco; Kim, In Ah; Aggarwal, Ajay; Lewison, Grant; Lu, Jiade J; Guedes de Castro, Douglas; Kong, Feng-Ming Spring; Afifi, Haidy; Sharp, Hamish; Vanderpuye, Verna; Olasinde, Tajudeen; Atrash, Fadi; Goethals, Luc; Corn, Benjamin W.
Affiliation
  • Abdel-Wahab M; Division of Human Health, International Atomic Energy Agency, Vienna, Austria. Electronic address: m.abdel-wahab@iaea.org.
  • Coleman CN; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Eriksen JG; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Lee P; Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
  • Kraus R; Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Harsdorf E; Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
  • Lee B; Department of Radiation Medicine, Loma Linda University, Loma Linda, CA, USA; Department of Radiation Oncology, Summa Health, Akron, OH, USA.
  • Dicker A; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Hahn E; Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, ON, Canada.
  • Agarwal JP; Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
  • Prasanna PGS; Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • MacManus M; Department of Radiation Oncology, Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Keall P; Image X Institute, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
  • Mayr NA; College of Human Medicine, Michigan State University, East Lansing, MI, USA.
  • Jereczek-Fossa BA; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Division of Radiotherapy, European Institute of Oncology, IRCCS, Milan, Italy.
  • Giammarile F; Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
  • Kim IA; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul, South Korea; Seoul National University, College of Medicine, Seoul, South Korea.
  • Aggarwal A; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Lewison G; Institute of Cancer Policy, King's College London, London, UK.
  • Lu JJ; Shanghai Proton and Heavy Ion Centre, Fudan University School of Medicine, Shanghai, China.
  • Guedes de Castro D; Department of Radiation Oncology, Hcor and Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
  • Kong FS; Department of Clinical Oncology, HKU-Shenzhen Hospital and Queen Mary Hospital, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China.
  • Afifi H; Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
  • Sharp H; Institute of Cancer Policy, King's College London, London, UK.
  • Vanderpuye V; National Center for Radiotherapy, Oncology and Nuclear Medicine, Korlebu Teaching Hospital, Accra, Ghana.
  • Olasinde T; Ahmedu Bello University Teaching Hospital, Zaria, Nigeria.
  • Atrash F; Augusta Victoria Hospital, Jerusalem, Israel.
  • Goethals L; Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
  • Corn BW; Shaare Zedek Medical Center, Jerusalem, Israel.
Lancet Oncol ; 25(6): e270-e280, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38821101
ABSTRACT
Although radiotherapy continues to evolve as a mainstay of the oncological armamentarium, research and innovation in radiotherapy in low-income and middle-income countries (LMICs) faces challenges. This third Series paper examines the current state of LMIC radiotherapy research and provides new data from a 2022 survey undertaken by the International Atomic Energy Agency and new data on funding. In the context of LMIC-related challenges and impediments, we explore several developments and advances-such as deep phenotyping, real-time targeting, and artificial intelligence-to flag specific opportunities with applicability and relevance for resource-constrained settings. Given the pressing nature of cancer in LMICs, we also highlight some best practices and address the broader need to develop the research workforce of the future. This Series paper thereby serves as a resource for radiation professionals.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiation Oncology / Developing Countries / Neoplasms Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiation Oncology / Developing Countries / Neoplasms Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article